Katherine E Burdick

Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.

2 papers in the library · 84 citations · publishing 2024-2025

Papers

Bipolar disorder.

Lancet (London, England) July 22, 2025 Balwinder Singh, Holly A Swartz, Alfredo B Cuellar-Barboza et al. 66 citations

Bipolar disorder, marked by hypomania or mania and predominantly depression, affects about 40 million people worldwide and carries substantial psychosocial, medical, and financial burdens, along with increased suicide risk. Diagnosis is often delayed due to symptom overlap with ADHD, major depression, psychotic disorders, and personality disorders. Recent research points to multigene risk and possible infectious and mitochondrial causes. Treatment combines pharmacotherapy, psychotherapy, and lifestyle changes, tailored to individual goals. Future priorities include expanding self-management psychosocial interventions, addressing treatment-resistant depression, deepening understanding of pathophysiology, and exploring novel options like ketamine, esketamine, and neuromodulation.

DOI: 10.1016/S0140-6736(25)01140-7 Full text Bipolar disorder Mental health treatment Disease etiology Diagnostic challenges

Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.

Psychiatry research May 1, 2024 Balwinder Singh, Sagar V Parikh, Jennifer L Vande Voort et al. 18 citations

In a nonrandomized, open-label clinical trial, 74 adults with treatment-resistant depression received three intravenous ketamine infusions, with an additional four infusions for those who remitted. After the acute phase, 53% (39/74) experienced remission of depression symptoms. Higher baseline language domain scores on the RBANS cognitive assessment were associated with greater odds of remission. No significant association was found between remission and baseline immediate or delayed memory, visuospatial, or attention scores. During the continuation phase, improvements in immediate and delayed memory and attention persisted, with additional gains in visuospatial and language domains. The findings suggest cognitive improvement, not deterioration, with serial ketamine administration.

DOI: 10.1016/j.psychres.2024.115829 Full text Neurocognition Open-label study Rbans Ketamine infusion +4